Pharmaceutical United Biotechnology Co., Ltd. (Pharmaceutical Union) announced that it will revise the annual cap on material procurement service agreements with the controlling shareholder Pharmacovigilance Biotechnology due to increased demand for raw materials due to increased demand for raw materials. The agreement was originally scheduled for November 3, 2023, and on March 31, 2024, the actual transaction amount is expected to exceed the original annual ceiling of RMB32.6 million based on unaudited management accounts. The Board of Directors decided to revise the maximum limits for 2024 and 2025 to RMB80.0 million and RMB75.0 million, respectively. This move is exempt from the Listing Rules and does not require the approval of independent shareholders. The FDA said the revision helps to ensure a stable supply of raw materials and is in the overall interests of the company and its shareholders.

Pharmaceutical United Biotechnology Co., Ltd. (Pharmaceutical Union) announced that it will revise the annual cap on material procurement service agreements with the controlling shareholder Pharmacovigilance Biotechnology due to increased demand for raw materials due to increased demand for raw materials. The agreement was originally scheduled for November 3, 2023, and on March 31, 2024, the actual transaction amount is expected to exceed the original annual ceiling of RMB32.6 million based on unaudited management accounts. The Board of Directors decided to revise the maximum limits for 2024 and 2025 to RMB80.0 million and RMB75.0 million, respectively. This move is exempt from the Listing Rules and does not require the approval of independent shareholders. The FDA said the revision helps to ensure a stable supply of raw materials and is in the overall interests of the company and its shareholders.